Cargando…
Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients
Several nucleotide analogues have been approved for use in treating hepatitis B virus (HBV) infection. Long-term exposure to therapy leads to the emergence of mutations within the HBV DNA polymerase gene, resulting in drug resistance, a major factor contributing to therapy failure. Chronic HBV patie...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673510/ https://www.ncbi.nlm.nih.gov/pubmed/38004634 http://dx.doi.org/10.3390/microorganisms11112622 |
_version_ | 1785140639708479488 |
---|---|
author | Gohar, Maryam Rehman, Irshad Ur Ullah, Amin Khan, Muhammad Ajmal Yasmin, Humaira Ahmad, Jamshaid Butt, Sadia Ahmad, Ajaz |
author_facet | Gohar, Maryam Rehman, Irshad Ur Ullah, Amin Khan, Muhammad Ajmal Yasmin, Humaira Ahmad, Jamshaid Butt, Sadia Ahmad, Ajaz |
author_sort | Gohar, Maryam |
collection | PubMed |
description | Several nucleotide analogues have been approved for use in treating hepatitis B virus (HBV) infection. Long-term exposure to therapy leads to the emergence of mutations within the HBV DNA polymerase gene, resulting in drug resistance, a major factor contributing to therapy failure. Chronic HBV patients from the Khyber Pakhtunkhwa province, Pakistan, who had completed 6 months of therapy participated in this study. Samples were collected from 60 patients. In this study, the entire reverse transcriptase domain of the HBV polymerase gene was amplified using nested polymerase chain reaction and sequenced. Drug-resistant mutations were detected in nine (22.5%) patients. All of these patients had lamivudine-resistant mutations (rtM204V + L180M), while seven individuals (17.5%) had both lamivudine- plus entecavir-resistant mutations (L180M + M204V + S202G). N236T, a mutation that gives rise to tenofovir and adefovir resistance, was observed in two (5%) patients. T184A, a partial drug-resistant mutation to entecavir, was found in five (12.5%) patients. Furthermore, other genotypic variants (100%) and vaccine escape mutations (5%) were additionally observed. Moreover, pN459Y (35%), pN131D (20%), pL231S (20%), pP130Q (17.5%), pS189Q (12.5%), pP161S (5%), pH160P (2.5%), pT322S (2.5%), and pA223S (2.5%) mutations in the polymerase gene, as well as sA166V (17.5%), sQ181K (12.5%), sV184R (7.5%), sA17E (5%), sP153S/K (5%), sW156C (5%), sC76Y (2.5%), and S132F (2.5%) mutations in the small surface gene, were identified for the first time in this study. Phylogenetic analysis showed that genotype D was predominant amongst the HBV carriers. Subtype D1 was found in most patients, while two patients were subtype D9. These novel findings may contribute to the body of knowledge and have clinical significance for treating and curing HBV infections in Pakistan. |
format | Online Article Text |
id | pubmed-10673510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106735102023-10-24 Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients Gohar, Maryam Rehman, Irshad Ur Ullah, Amin Khan, Muhammad Ajmal Yasmin, Humaira Ahmad, Jamshaid Butt, Sadia Ahmad, Ajaz Microorganisms Article Several nucleotide analogues have been approved for use in treating hepatitis B virus (HBV) infection. Long-term exposure to therapy leads to the emergence of mutations within the HBV DNA polymerase gene, resulting in drug resistance, a major factor contributing to therapy failure. Chronic HBV patients from the Khyber Pakhtunkhwa province, Pakistan, who had completed 6 months of therapy participated in this study. Samples were collected from 60 patients. In this study, the entire reverse transcriptase domain of the HBV polymerase gene was amplified using nested polymerase chain reaction and sequenced. Drug-resistant mutations were detected in nine (22.5%) patients. All of these patients had lamivudine-resistant mutations (rtM204V + L180M), while seven individuals (17.5%) had both lamivudine- plus entecavir-resistant mutations (L180M + M204V + S202G). N236T, a mutation that gives rise to tenofovir and adefovir resistance, was observed in two (5%) patients. T184A, a partial drug-resistant mutation to entecavir, was found in five (12.5%) patients. Furthermore, other genotypic variants (100%) and vaccine escape mutations (5%) were additionally observed. Moreover, pN459Y (35%), pN131D (20%), pL231S (20%), pP130Q (17.5%), pS189Q (12.5%), pP161S (5%), pH160P (2.5%), pT322S (2.5%), and pA223S (2.5%) mutations in the polymerase gene, as well as sA166V (17.5%), sQ181K (12.5%), sV184R (7.5%), sA17E (5%), sP153S/K (5%), sW156C (5%), sC76Y (2.5%), and S132F (2.5%) mutations in the small surface gene, were identified for the first time in this study. Phylogenetic analysis showed that genotype D was predominant amongst the HBV carriers. Subtype D1 was found in most patients, while two patients were subtype D9. These novel findings may contribute to the body of knowledge and have clinical significance for treating and curing HBV infections in Pakistan. MDPI 2023-10-24 /pmc/articles/PMC10673510/ /pubmed/38004634 http://dx.doi.org/10.3390/microorganisms11112622 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gohar, Maryam Rehman, Irshad Ur Ullah, Amin Khan, Muhammad Ajmal Yasmin, Humaira Ahmad, Jamshaid Butt, Sadia Ahmad, Ajaz Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients |
title | Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients |
title_full | Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients |
title_fullStr | Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients |
title_full_unstemmed | Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients |
title_short | Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients |
title_sort | phylogenetic analysis and emerging drug resistance against different nucleoside analogues in hepatitis b virus positive patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673510/ https://www.ncbi.nlm.nih.gov/pubmed/38004634 http://dx.doi.org/10.3390/microorganisms11112622 |
work_keys_str_mv | AT goharmaryam phylogeneticanalysisandemergingdrugresistanceagainstdifferentnucleosideanaloguesinhepatitisbviruspositivepatients AT rehmanirshadur phylogeneticanalysisandemergingdrugresistanceagainstdifferentnucleosideanaloguesinhepatitisbviruspositivepatients AT ullahamin phylogeneticanalysisandemergingdrugresistanceagainstdifferentnucleosideanaloguesinhepatitisbviruspositivepatients AT khanmuhammadajmal phylogeneticanalysisandemergingdrugresistanceagainstdifferentnucleosideanaloguesinhepatitisbviruspositivepatients AT yasminhumaira phylogeneticanalysisandemergingdrugresistanceagainstdifferentnucleosideanaloguesinhepatitisbviruspositivepatients AT ahmadjamshaid phylogeneticanalysisandemergingdrugresistanceagainstdifferentnucleosideanaloguesinhepatitisbviruspositivepatients AT buttsadia phylogeneticanalysisandemergingdrugresistanceagainstdifferentnucleosideanaloguesinhepatitisbviruspositivepatients AT ahmadajaz phylogeneticanalysisandemergingdrugresistanceagainstdifferentnucleosideanaloguesinhepatitisbviruspositivepatients |